Background: Ewing sarcoma is a cancer of bone and soft tissue. Despite aggressive treatment, survival remains poor, particularly in patients with metastatic disease. Failure to treat Ewing sarcoma is due to the lack of understanding of the molecular pathways that regulate metastasis. In addition, no molecular prognostic markers have been identified for Ewing sarcoma to risk stratify patients.
INTRODUCTION
Ewing sarcoma family of tumors is a group of poorly differentiated malignant cancers of bone and soft tissue. The overall 5-year diseasefree survival for localized Ewing sarcoma treated with surgery, radiation therapy, and multiagent chemotherapy is approximately 70%. 1, 2 In contrast, patients with metastases have a 5-year survival rate of approximately 20-30%, despite aggressive multimodal therapy. 2, 3 Over the last 30 years, only minor progress has been made in the treatment of Ewing sarcoma particularly for metastatic disease. 4 Majority Abbreviations: CHOC, Children's Hospital Orange County; EMT, Epithelial-mesenchymal transition; GFP, green fluorescent protein; IHC, immunohistochemistry; MET, Mesenchymal-epithelial transition; NTC, nontarget coding; RCHSD, Rady Children's Hospital San Diego of the deaths from Ewing sarcoma are due to metastasis, which makes blocking metastasis crucial for effective treatment. 5 These therapies will only be possible once we have a better molecular understanding of the pathogenic mechanism of metastatic spread.
In Ewing sarcoma, the EWS-ETS gene fusion is the primary mechanism promoting tumorigenesis and also plays a role in metastasis. 6, 7 The EWS-ETS fusion gene is thought to promote metastasis through decreased cellular adhesions rather than promoting cell migration and invasion. 8 This passive dissemination of cancer cells can occur because the primary cancer site is often bone where the marrow space would promote passive transfer into the circulation. However, this does not explain how soft tissue Ewing sarcoma metastasize or how the cells colonize secondary sites. In fact, EWS/FLI knockdown cells tend to seed the lung better than their parental cells with EWS/FLI expression. 8 This leads us to believe that metastasis requires more than the EWS/FLI gene fusion and more research is needed to better understand the mechanism of metastasis in Ewing sarcoma.
The origin of Ewing sarcoma cells also remains difficult to identify given the nature of the poorly differentiated cells. Several studies indicate that there is a high similarity in gene expression signatures between Ewing sarcoma and fetal and neuronal tissues. [9] [10] [11] Some reports suggest that Ewing sarcoma cell lineage could be traced back to neural crest cells. 10, 11 Neural crest cells are highly motile cells that migrate throughout the body to form bone, soft tissues, and other tissues during embryogenesis. Twist1 transcription factor plays a major role in regulating cell movement and tissue reorganization during neural crest development. 12, 13 The extensive cell migration during embryogenesis shares many similarities with tumor cell invasion and metastasis. 14 A number of previous studies have demonstrated a critical role of Twist1 in driving tumor metastasis in breast cancer and skin cancer models. 12, 15 Many studies have also shown that Twist1 expression was associated with aggressive human cancers including melanomas and neuroblastoma, 16, 17 both of which originate from the neural crest.
ZEB2 transcription factor, like Twist1, is also involved in normal neural crest development. Higher levels of ZEB2 expression has already been shown to correlate with increased patient metastasis in Ewing sarcoma. 18 EWS/FLI is reported to prevent mesenchymal differentiation while ZEB2 prevents epithelial differentiation. 18 This results in Ewing sarcoma cell possessing both epithelial and mesenchymal characteristics, thus promoting both primary tumor growth and metastasis.
The role of Twist1 and Zeb2 in tumor metastasis have been largely contributed to their ability to induce epithelial to mesenchymal transition, thus allowing carcinoma cell dissemination from primary tumor to distant organs. 15 Although Ewing sarcoma is not an epithelial tumor and may have a unique mode of metastasis separate from that of epithelial-derived carcinomas, 19, 20 they could still use similar cellular machineries for migration and invasion that are activated by Twist1 and Zeb2 to promote neural crest cell formation.
Given the similarity of Ewing sarcoma to fetal and neural tissues, we hypothesize that genes regulating neural crest cells migration are reactivated to allow Ewing sarcoma cells to metastasize. In this study, we test the hypothesis that Twist1, a regulator of neural crest development, plays a critical role in metastatic Ewing sarcoma.
MATERIALS AND METHODS

Ewing sarcoma patient tumor samples
We used microarray analysis results for Ewing sarcoma patient tumor samples from the R2 Genomics Analysis and Visualization platform (http://r2.amc.nl). The Dirksen and Savola database was used for analysis of Twist1 gene expression for overall and event-free survival. The "Kaplan Scan" feature on the R2 platform was used to separate each database into two groups based on Twist1 gene expression and to create a Kaplan-Meier curve based on the log-rank test. The "Kaplan Scan" uses statistical testing instead of an average or median expression cutoff to separate into a high or low Twist1 expressing group. The same high/low groups established using the "Kaplan Scan" method for overall survival was used to analyze event-free survival. 
Immunohistochemistry
Five micrometer serial sections of paraffin-embedded patient samples were rehydrated through xylene and graded alcohols. Antigen retrieval was used using a pressure cooker and Diva Decloaker (Biocare, Concord, CA). Endogenous avidin/biotin was blocked using Vec- (10 g/ml), human EGF (10 ng/ml), L-glutamine (1.2 g/ml), and hydrocortisone (0.5 g/ml). All cell lines were grown to maximum 80% confluency before passaging. were then selected with 6 g/ml puromycin. RDES cells were selected with 7 g/ml blasticidin.
Viral production and infection
Plasmids
The shTwist3 and shTwist7 pSP108 lentiviral constructs and the Twist1 cDNA in pWZL-Blast (pWB) retroviral vector have been previously described. 12, 14 The pWZL-Blast-GFP vector was obtained from Addgene. A nontarget coding (NTC) siRNA oligo was used as control. The NTC sequence is not known to match any human coding cDNA. The NTC sequence was 5' CCGGGCGCGATA GCGCTAATAATTTCTCGAGAAATTATTAGCGCTATCGCGCTTTTT-3' .
To generate green fluorescent protein (GFP) expressing cells, we coinfected the cells with PRRL-GFP vectors. The infection rate of the lentivirus, determined by fluorescence, was greater than 90%. 
Tumor xenograft model
Migration and invasion assay
In the migration assay of A673 cel lines, 250 l of the cell suspen- 
RESULTS
Expression of TWIST1 is significantly associated with metastatic Ewing sarcoma
To initially address the involvement of TWIST1 in Ewing sarcoma metastasis, we evaluated the association of Twist1 mRNA expression in Ewing sarcoma tumor samples with patient outcomes using the R2 Genomic Analysis and Visualization platform (http://r2.amc.nl).
Microarray-based gene expression analysis of the Dirksen-85 and Savola Ewing sarcoma patient data set was used for analysis. 21, 22 Low/high cut off was established using the Kaplan scan feature of R2 platform. Higher expression of Twist1 was significantly associated with decreased overall survival (Figs. 1A and 1C ). Twist1 expression on event-free survival was significant in the Dirksen database when using the same low/high groups established for overall free survival analysis (Fig. 1B) .
We further analyzed primary human Ewing sarcoma samples to detect the protein expression of TWIST1, a key regulator of neural crest formation and a key player in metastasis. Forty-one patient samples from RCHSD and CHOC were analyzed for this study using IHC staining for TWIST1 expression. Patient characteristics from RCHSD and CHOC were similar to historical cohorts. There was a slight male predominance and a median age of 11.6 years. However, our cohort had an increased number of patients with metastatic disease at 59% that corresponded with a decreased overall survival compared to historical cohorts (Supplementary Table S1 ).
All patient tumor tissue was strongly positive for Ewing sarcoma marker CD99, suggesting that the samples were the correct tumor type ( Fig. 2A) . A pediatric pathologist retrospectively reviewed the patient samples and agreed with the Ewing sarcoma diagnosis. RCHSD and CHOC routinely test for EWS rearrangement to confirm an Ewing sarcoma diagnosis. Prior studies suggest that upwards of 95% of Ewing sarcoma patients have an EWS rearrangement detected at F I G U R E 1 Twist1 mRNA expression correlates with poor outcome in Ewing sarcoma patients. Using the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl), patients with Ewing sarcoma were divided into high (blue) and low (red) Twist1 expression groups and a Kaplan-Meier survival curve was generated. The Dirksen 85 and Savola Ewing sarcoma tumor data set was used for analysis. Both event-free survival (A and C) and overall survival (B and D) are presented with the number of patients shown in parenthesis diagnosis. 23, 24 However, results on molecular testing for EWS rearrangements were not available for review.
Interestingly, 83% (20/24) of tumor samples from patients with metastatic diseases showed strong positive nuclear staining of Twist1 ( Figs. 2A and 2B ). In contrast, only 35% (six of 17) of tumor samples from patients with localized tumors showed positive Twist1 staining (Fig. 2B) . Furthermore, we found that Twist1 positivity was correlated with poor survival in patients with Ewing sarcoma, consistent with the results from the Dirksen and Savola patient data set (Fig. 2C) .
Survival curves based on Twist 1 expression was similar to survival curves based on presence of metastasis (Fig. 2C) . Survival curve analysis excluded one patient consented for the study because the survival data were not available. Three other patients died from secondary AML from chemotherapy, which is unlikely related to Twist1 expression, so they were removed from survival analysis. When separating Twist1 expression within the metastatic and nonmetastatic group, we noticed that Twist1 expression correlated with worse survival within each group (Fig. 2D) . The correlation however was not 
Twist1 is required for Ewing sarcoma metastasis
We next tested the biological requirement for Twist1 in mediating Ewing sarcoma tumor cell invasion and metastasis. We first evaluated the expression of Twist1 in a number of established human Ewing sarcoma tumor cell lines, including TC32, TC71, A673, EWS-502, RD-ES, and SK-N-MC. Real-time PCR and western blotting analysis showed that indeed expression of Twist1 mRNA and protein is easily detected in many human Ewing sarcoma cell lines (Figs. 3A and 3B) .
We chose the A673 and TC32 Ewing sarcoma cell lines to establish human Ewing sarcoma xenograft model given their short doubling time, extensive publications using those cell lines as Ewing sarcoma models, and their ability to metastasize in mice. We infected GFP expressing-A673 and TC32 Ewing cells with a lentiviral vector carrying either shRNA against Twist1 (shTwist3, shTwist5, or shTwist7) or a control shRNA (shNCT). Expression of GFP in tumor cells enabled us to detect micrometastases composed of very few tumor cells in the lung.
We verified specific knockdown of TWIST1 protein by western blot (Fig. 3C ). A673 cells expressing shTwist#3 or shTwist#7 generated primary tumors with similar growth kinetics and similar final weight as the control cells (Fig. 4B) . However, mice carrying A673 tumors expressing shRNAs against Twist1 presented significantly fewer lung metastases, average 2 nodules per mice, compared to the control xenografts, average 32 nodules per mice (Fig. 4B) . IHC for Twist1 in the primary tumor confirm TWIST1 knockdown in the mice (Fig. 4A) . We obtained similar results for the TC32 cell line (Fig. 4D) . Together, these data strongly support the notion that Twist1 is required for Ewing sarcoma metastasis.
TWIST1 promote Ewing sarcoma cell migration and invasion
Next, we wanted to determine the effects of Twist1 on the migration and invasion capability of Ewing sarcoma cells. We found that knockdown of Twist1 in A673 cells led to significant decrease in cell migration toward a high serum gradient (Fig. 5B) . In addition, knockdown of Twist1 also decreased cell invasion through matrigel (Fig. 5C ). To further generalize the role of Twist1 on migration and invasion, we over- from typical undifferentiated Ewing sarcoma of bone to differentiated primitive neuroectodermal tumors. 25 The EWS-ETS translocation has been shown to act as determinant of cell lineage. This chimeric fusion gene upregulates genes important to neural crest development but inhibits terminal differentiation creating an undifferentiated cell with characteristics of both epithelial and mesenchymal tumors. 10 Our study suggests that Twist1, normally expressed during neural crest development, is involved in metastasis in Ewing sarcoma by promoting invasion and metastasis. TWIST1 expression correlates with poorer prognosis within the metastatic and nonmetastatic patient groups. These results indicate that TWIST1 expression could be used for treatment stratification within the nonmetastatic or metastatic groups. Our study, however, is limited by the small sample size due to the rare incidence of Ewing sarcoma cases. There are only about 200 cases of Ewing sarcoma diagnosed in the United States per year.
Although the small number of cases shows a significant correlation of TWIST1 expression and overall survival, the positive predictive value is currently low and could be further improved with larger sample sizes.
Currently, Ewing sarcoma patients are being stratified for treatment purposes solely based on the presence of metastatic lesions.
Unfortunately given the rarity of Ewing sarcoma, we will need to rely on data collected from small cohorts to explore new treatment options.
Our study suggests that Twist1 expression can stratify patients with localized diseases who are at higher risk for relapse and for those patients, intensified therapy upfront could prevent metastasis and Data were presented as mean ± SEM. **P < 0.01 by ANOVA followed by Bonferroni test ultimately improve overall survival. As a transcription factor, Twist1 could induce a number of target genes, including Snail2, 26 PDGFRa, 27 and Akt2. 28 Future studies are needed to evaluate their roles in Ewing sarcoma metastasis and their potential to serve as therapeutic targets to block metastasis.
Future prospective studies are needed to determine if Twist1 expression could be determined in a timely manner to modify treatment plan. A prospective study will also allow comparison of patients treated uniformly with interval compression therapy. Our patient samples were collected as early as 1998 prior to the start of interval compression therapy for Ewing sarcoma in 2001. 29 The small sample size and varied treatments used for our patient cohort may have lead to some sampling bias. Further larger prospective studies looking into Twist1 in Ewing sarcoma is warranted.
Since the most common site of disease recurrence for Ewing sarcoma is the lung, a drug targeting this unique metastatic pathway could be used in conjunction with cytotoxic therapy to prevent lung metastasis. Previous data show that Ewing sarcoma tends to metastasize early and local control alone will not prevent recurrence at distant sites. The addition of targeted therapy against this metastatic pathway instead of additional cytotoxic therapy could minimize long-term sequela of therapy and decrease disease metastasis and recurrence to improve overall survival.
Understanding the mechanism of metastasis in Ewing sarcoma is key to finding targeted therapies that will reduce metastases and improve survival. Our work suggests that Twist1 transcription factor and its key downstream targets could be potential drug targets to inhibit the metastasis program in Ewing sarcoma and other neural crest-derived cancers.
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